Phase 2 N=72 Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer
Breast Cancer
Primary: Five-Year Relapse-free Survival — 47; 55 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=94 Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
HIV-1 Infection
Primary: Difference Between [Change From Week 24 to Week 44] and [Change From Baseline to Week 20] in log10 IL-6 — -0.08; -0.08 log10 pg/mL — p=0.94
Phase 2 N=487 Study of AERAS-402 in Healthy Infants
Tuberculosis
Primary: Adverse Events Collected Per Subject — 94.2; 96.1; 100.0; 100.0 percentage of subjects with an AE
Phase 2 N=316 A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
Hepatitis C, Chronic
Primary: Percentage of Participants in Each Treatment Group With Sustained Virologic Response 12 Weeks Post-treatment — 90.9; 95.2; 90.0; 100 Percentage of participants — p=0.381
Phase 2 N=307 A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Primary: Progression-free Survival — 232; 245 days
Phase 2 N=215 Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
HIV Infections · Cognition Disorders
Primary: Change in Global Neurocognitive Performance z Score From Baseline — 0.24; 0.16 z score — p=0.18
Phase 2 N=16 5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome
Myelodysplastic Syndrome
Primary: One Year Overall Survival of Allogeneic Transplant Recipients After Transplantation — 50 percentage of participants
Phase 2 N=20 Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection
Kidney Transplantation
Primary: Post-transplant Biopsy to Identify Rejection Episodes — 2; 3 Episode of rejection
Phase 2 N=16 A Clinical Study of the Performance of a Glucose Blinding Protein-Based Continuous Glucose Monitor (GBP CGM)
Type 1 Diabetes Mellitus
Primary: Absolute Relative Difference (ARD) — 19.1; 14.9; 21.8; 20.4 percentage of error
Phase 2 N=31 Carvedilol for Psychostimulant Dependence
Cocaine Dependence · Cocaine Withdrawal
Primary: Urine Toxicology Screens — 38.33; 41.85 percentage of cocaine negative urines — p=0.05
Phase 2 N=128 Evaluation of GSK561679 in Women With Post-Traumatic Stress Disorder
Stress Disorders, Post-Traumatic
Primary: Efficacy, Measured by Change in the Clinician-Administered PTSD Scale (CAPS) Score — -26.02; -27.33 Score on a scale
Phase 2 N=17 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
Adult Fibrosarcoma · Adult Leiomyosarcoma · Adult Liposarcoma
Primary: Disease Control Rate, Defined as the Number of Patients Who Achieved Complete Response, Partial Response or Stable Disease For a Period of More Than 4 Months. — 0…
Phase 2 N=48 Lamotrigine Monotherapy in Pediatric Bipolar Disorder
Bipolar Disorder
Primary: Young Mania Rating Scale (YMRS), — 19.61; 7.06; 5.68 units on a scale
Phase 2 N=178 Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma
Metastatic Osteosarcoma · Recurrent Adult Soft Tissue Sarcoma · Recurrent Osteosarcoma
Primary: Progression-free Survival Rate, Defined as CR + PR + SD, as Assessed by RECIST Criteria — 4; 57; 98 participants
Phase 2 N=237 Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
Rheumatoid Arthritis
Primary: Number of Participants With American College of Rheumatology Response of 20 (ACR20) at 16 Weeks — 22; 20; 23; 18 Participants